Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Revenue (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Revenue for 6 consecutive years, with $90000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 2900.0% to $90000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $120000.0, a 605.88% increase, with the full-year FY2024 number at $37000.0, down 99.82% from a year prior.
  • Revenue was $90000.0 for Q3 2025 at 4D Molecular Therapeutics, up from $15000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $20.2 million in Q3 2023 to a low of -$19000.0 in Q4 2023.
  • A 5-year average of $2.2 million and a median of $162000.0 in 2022 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 3940.8% in 2023; the steepest drop was 101.52% in 2023.
  • 4D Molecular Therapeutics' Revenue stood at $92000.0 in 2021, then skyrocketed by 1256.52% to $1.2 million in 2022, then crashed by 101.52% to -$19000.0 in 2023, then skyrocketed by 105.26% to $1000.0 in 2024, then surged by 8900.0% to $90000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Revenue are $90000.0 (Q3 2025), $15000.0 (Q2 2025), and $14000.0 (Q1 2025).